Several targets have been selected in GBM including as EGFRvIII, IL13Ra2 and HER2 [152–155], though little clinical efficacy has been observed, likely due to a combination of factors including the immunosuppressive and metabolically-stressful tumor microenvironment, tumor heterogeneity, antigen escape and CAR-T exhaustion [116]. The gene discussed is ERBB2; the disease is neoplasm.